Building an AI Management System for Pharma Companies

Why Pharma Can't Just Borrow a Generic AI Governance Template

Every pharma company I talk to right now is running at least one AI system somewhere in its operation, whether it's a machine learning model flagging deviations in batch records, an NLP tool triaging adverse event reports, or a predictive model supporting drug discovery. Very few of them have a formal system for governing those tools. They have a policy document, maybe a committee that meets quarterly, and a lot of hope.

That gap matters more in pharma than almost anywhere else. A marketing team's AI governance failure produces an embarrassing chatbot transcript. A pharma AI governance failure can produce a batch release decision made on a model nobody validated, or a regulatory submission built on data an AI system quietly mislabeled. The stakes are why regulators are moving faster here than in most sectors, and why "AI management system" has stopped being an abstract governance concept and started being something FDA reviewers and EMA assessors expect to see documented.

In my work advising regulated manufacturers on ISO 42001 and AI governance design, the question I get most often isn't "should we build an AI management system" — most teams have accepted that they need one. The question is how to build one that satisfies ISO/IEC 42001:2023, holds up under FDA scrutiny, and doesn't duplicate the computerized system validation program they already run under 21 CFR Part 11. This guide walks through that build.

What an AI Management System Actually Is

An AI management system (AIMS) is a structured, documented set of policies, roles, risk processes, and controls that governs how an organization designs, deploys, monitors, and retires AI systems. It is not a single tool or a validation protocol. It's the governance layer that sits above your individual AI use cases and makes sure each one gets assessed, approved, monitored, and eventually decommissioned the same disciplined way, regardless of which department built it or which vendor sold it.

ISO/IEC 42001:2023 is the first international management system standard written specifically for this purpose, and it's built on the same Annex SL high-level structure as ISO 9001 and ISO 27001. That structural similarity is not an accident, and it's the reason pharma companies with mature quality systems tend to move faster on AIMS implementation than companies building governance from a blank page. If your quality unit already runs a document control system, a CAPA process, and a management review cadence, you have most of the scaffolding an AIMS needs. You're extending it, not starting over.

ISO 42001:2023 as the Backbone

ISO/IEC 42001:2023 follows the familiar Plan-Do-Check-Act structure: Context of the Organization (Clause 4), Leadership (Clause 5), Planning (Clause 6), Support (Clause 7), Operation (Clause 8), Performance Evaluation (Clause 9), and Improvement (Clause 10). For pharma teams, three clauses do most of the heavy lifting.

Clause 6.1.2 requires a formal AI risk assessment before a system enters production use, evaluating impacts to individuals, groups, and society, not just technical performance. This is a materially different lens than the one most pharma teams use for computerized system validation, which is oriented toward process control and data integrity rather than downstream human impact. An AI system that correctly executes its intended function can still fail a Clause 6.1.2 assessment if it introduces bias into a patient-facing triage decision or obscures the basis for a batch disposition recommendation.

Clause 8.1 through 8.4 govern operational planning and control, including the ongoing AI risk assessment and AI system impact assessment that carry through the system's operational life, not just its initial deployment. Annex A then supplies the control catalog: A.5 covers assessing impacts of AI systems, A.6 covers the AI system life cycle, and A.7 covers data for AI systems, including provenance, quality, and labeling. For a pharma organization, A.7 is where GxP data governance and AI governance overlap most directly, and it's worth building that overlap intentionally rather than running two parallel data quality programs that occasionally disagree with each other.

None of this replaces your existing quality management system. It extends it. A company already certified to ISO 9001 or operating under 21 CFR Part 211 has a management review process, a document hierarchy, and an internal audit program. The AIMS adds AI-specific risk criteria, a dedicated AI system inventory, and impact assessment methodology to that existing structure rather than standing up a separate one.

Mapping AI Governance to FDA and EMA Expectations

FDA has been building AI-specific expectations in pieces rather than issuing a single comprehensive rule, which is part of why pharma teams find the landscape confusing. Here's how the pieces fit together.

FDA's January 2021 Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan introduced the predetermined change control plan, or PCCP, as the mechanism for pre-authorizing planned model updates without requiring a new submission for every change. If your organization develops or uses adaptive AI models in a SaMD context, your AIMS should have a documented process for building and maintaining PCCPs, and that process belongs inside Clause 8's operational controls, not as a side document your regulatory affairs team keeps separately.

For drug and biological products specifically, FDA's January 2025 draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (Docket FDA-2024-D-4689), recommends a risk-based credibility assessment framework. The higher the model risk and the more the regulatory decision relies on the model's output, the more rigorous the evidence of that model's fitness for purpose needs to be. That's the same logic ISO 42001's Clause 6.1.2 risk assessment already asks you to apply. Building your credibility assessment methodology as an extension of your ISO 42001 risk assessment, rather than as a separate FDA-specific exercise, keeps the two frameworks from drifting apart as both evolve.

On the records side, 21 CFR Part 11 doesn't carve out an exception for AI. Any AI system that creates, modifies, or maintains records supporting a regulatory submission or a GxP decision needs audit trails, access controls, and change management equivalent to what you'd require of any other validated computerized system. This is where AIMS and computerized system validation genuinely need to talk to each other: your AI system inventory under Annex A.6 should map directly to your validated systems inventory, not live in a separate spreadsheet that nobody reconciles.

The EU adds a layer on top of all this. Regulation (EU) 2024/1689, the EU AI Act, classifies AI systems used as a safety component of a medical device already subject to third-party conformity assessment as high-risk under Article 6(1). That classification triggers the Article 9 risk-management-system obligations regardless of where the manufacturer is headquartered. A pharma company selling into the EU market needs its AIMS risk assessment to satisfy both ISO 42001 and Article 9, and building those as one process rather than two parallel compliance exercises saves real time during EMA and notified body interactions.

Comparing the Major Frameworks

Pharma teams often ask which framework to build around first. In practice you need elements of all three, but they serve different purposes.

The practical answer for most regulated manufacturers is to build the AIMS on ISO 42001's structure because it's the only one of the four that's auditable and certifiable, then use NIST AI RMF's function language internally where it helps teams reason about risk, and treat the FDA guidance documents and EU AI Act as the specific regulatory requirements your ISO 42001 risk criteria need to satisfy.

Core Components of a Pharma AI Management System

• AI system inventory. You cannot govern what you haven't catalogued. Every AI or ML-enabled tool in the organization, whether built in-house, embedded in a vendor's LIMS or eQMS, or run as a standalone model, needs an entry: its intended use, its risk classification, its owner, and its validation status. Vendor-embedded AI is the one teams miss most often, because procurement bought "the software" without anyone flagging that a predictive maintenance module or an automated deviation classifier inside it is itself an AI system requiring its own risk assessment.
• Risk and impact assessment methodology. This is the connective tissue between ISO 42001 Clause 6.1.2, FDA's credibility assessment framework, and EU AI Act Article 9. Build one methodology with criteria specific enough to satisfy all three, rather than three separate checklists that produce inconsistent risk ratings for the same system.
• Data governance for AI. Annex A.7 requires documented control over the data used to train, validate, and monitor AI systems, including provenance and quality criteria. In a GxP environment, this needs to reconcile with your existing data integrity program (ALCOA+ principles) rather than introduce a competing standard for what "good data" means.
• Human oversight and escalation. Every AI system touching a GxP decision needs a defined point where a qualified human reviews and can override the model's output before that output becomes a record. This isn't a suggestion under either ISO 42001 or FDA's draft guidance; it's the mechanism regulators actually check for during inspection.
• Monitoring and drift detection. AI models degrade in ways static software doesn't. Clause 9 performance evaluation requires ongoing monitoring against defined criteria, and for pharma applications that monitoring plan should specify what triggers a re-validation event, not just what triggers an alert.
• Change management tied to CSV. Every model update, retrain, or parameter change needs to flow through the same change control discipline as any other GxP system change, cross-referenced to the PCCP where one exists.

A Realistic Implementation Roadmap

Follow this sequence:

1. Build the inventory before the policy. I've seen organizations write a beautiful AI governance policy and then discover, six months later, that they never catalogued the four AI-enabled modules already running inside vendor software. Get the inventory built first, even in rough form, because it tells you the actual scope of the risk assessment work ahead.
2. Build the risk assessment methodology and run it retroactively against every system already in the inventory. This does two things: it gives you a real risk-tiered picture of where you stand, and it surfaces the gaps in documentation and validation that need to close before you'd want an auditor or an FDA investigator looking at any of it.
3. Map your AIMS structure onto your existing quality management system rather than building parallel infrastructure. If you have a document control system, extend it to AI-specific document types. If you have a management review cadence, add AI risk and performance as a standing agenda item rather than scheduling separate AI governance reviews that quality leadership never attends.
4. Formalize the policy, train the organization, and engage a certification body for a gap assessment before the formal audit, if certification is part of the plan. Certification is a milestone in this process, not the starting point, and treating it as the starting point is how organizations end up with a policy binder that doesn't reflect how AI actually gets used in the building.

Where Organizations Get This Wrong

The most common failure I see is treating the AIMS as a compliance artifact owned entirely by quality or regulatory affairs, disconnected from the data science and IT teams actually building and deploying the models. An AI management system that the people building AI systems don't know exists isn't governing anything. The second most common failure is under-scoping the AI system inventory, usually by excluding vendor-embedded AI on the theory that "we didn't build it, so it's not our AI system to govern." Under both ISO 42001 and FDA's guidance, if you deployed it and it drives a decision in your process, it's yours to govern, regardless of who wrote the code.

If you're earlier in the process and still deciding whether ISO 42001 or a different framework should anchor your program, our guide to choosing an ISO 42001 consultant walks through what to look for, and our healthcare and pharma practice page covers the sector-specific considerations in more depth than a single article can.

Frequently Asked Questions

Does ISO 42001 certification satisfy FDA requirements for AI in drug development? No. ISO 42001 certification demonstrates a functioning management system for governing AI, but it doesn't substitute for FDA's own review of a specific AI model's credibility under guidance like the January 2025 draft guidance (Docket FDA-2024-D-4689). Certification strengthens your submission by showing a mature governance process behind the model; it doesn't replace the model-specific evidence FDA requires.

Do we need a separate AI management system if we already have a validated computerized systems program under Part 11? You need to extend your existing program, not replace it. Part 11 governs records and signatures; an AIMS governs the broader lifecycle of the AI system itself, including risk assessment, data governance, and human oversight. The two should share an inventory and a change control process rather than operate as parallel systems.

What counts as an "AI system" for inventory purposes? Any software component that uses machine learning, natural language processing, or similar techniques to generate predictions, classifications, or recommendations that influence a business, quality, or regulatory decision. This includes vendor-embedded modules inside LIMS, eQMS, or ERP platforms, not just custom-built models.

How long does it take to build and certify an AI management system in pharma? Timelines vary with organizational size and existing QMS maturity, but building the inventory and risk methodology typically takes several months before an organization is ready for a certification-body gap assessment. Companies with an established ISO 9001 or ISO 13485 quality system generally move faster because the document control and management review infrastructure already exists.

Does the EU AI Act apply to a US-based pharma company? Yes, if the company places AI-enabled products or services on the EU market or if its AI system is used as a safety component of a medical device subject to EU conformity assessment. Regulation (EU) 2024/1689's Article 6(1) high-risk classification applies based on where the product is marketed and how it's used, not where the manufacturer is headquartered.

Last updated: 2026-08-23